Molecular Targeting Technologies Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Molecular Targeting Technologies General Information

Description

Operator of a biotechnology company intended to develop novel radiopharmaceuticals for disease treatment and diagnosis. The company's technology focuses on radiolabeling the targeting molecule that assists in the early detection of tumor response to chemotherapy, cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome, and transplant rejection, enabling medical researchers to help in drug development and reduce patient treatment time with proper diagnoses.

Contact Information

Website
www.mtarget.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 833 Lincoln Avenue
  • Unit 9
  • West Chester, PA 19380
  • United States
+1 (610)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • 833 Lincoln Avenue
  • Unit 9
  • West Chester, PA 19380
  • United States
+1 (610)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Molecular Targeting Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator Completed Generating Revenue
4. Grant 01-Feb-2019 Completed Generating Revenue
3. Grant 09-Apr-2018 Completed Generating Revenue
2. Grant 01-Jan-2018 $8.45M Completed Generating Revenue
1. University Spin-Out 01-Jan-2011 Completed Startup
To view Molecular Targeting Technologies’s complete valuation and funding history, request access »

Molecular Targeting Technologies Patents

Molecular Targeting Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4196173-A1 Compounds and compositions for tumor detection and surgical guidance Pending 14-Aug-2020
EP-4196173-A4 Compounds and compositions for tumor detection and surgical guidance Pending 14-Aug-2020
EP-4013396-A1 Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes Inactive 15-Aug-2019
EP-4013396-A4 Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes Inactive 15-Aug-2019
US-11090309-B2 Anti-thrombotic agents and methods of use thereof Active 30-Jun-2017 A61K31/555
To view Molecular Targeting Technologies’s complete patent history, request access »

Molecular Targeting Technologies Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
United States Department of Agriculture Government
U.S. Department of Health and Human Services Government
University of Notre Dame University
Jefferson Accelerator Zone Accelerator/Incubator
To view Molecular Targeting Technologies’s complete investors history, request access »

Molecular Targeting Technologies FAQs

  • When was Molecular Targeting Technologies founded?

    Molecular Targeting Technologies was founded in 2011.

  • Where is Molecular Targeting Technologies headquartered?

    Molecular Targeting Technologies is headquartered in West Chester, PA.

  • What industry is Molecular Targeting Technologies in?

    Molecular Targeting Technologies’s primary industry is Biotechnology.

  • Is Molecular Targeting Technologies a private or public company?

    Molecular Targeting Technologies is a Private company.

  • What is Molecular Targeting Technologies’s current revenue?

    The current revenue for Molecular Targeting Technologies is .

  • Who are Molecular Targeting Technologies’s investors?

    United States Department of Agriculture, U.S. Department of Health and Human Services, University of Notre Dame, and Jefferson Accelerator Zone have invested in Molecular Targeting Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process